Results 171 to 180 of about 66,618 (347)
C4d immunostaining in acute humoral rejection after ABO blood group-incompatible liver transplantation [PDF]
, 2006 Ulf Neuman, P. Neuhaus
openalex +1 more source
Advanced Therapeutics, EarlyView.This review covers the mechanical forces experienced by immune cells through cell–cell and cell–extracellular matrix interactions and how these forces influence their receptors and functions. These relationships between forces and cellular functions can be exploited using engineering techniques to modify the physical properties of materials for novel ...
Yu‐Chang Chen +2 more
wiley +1 more source
CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility. [PDF]
Blood Transfus, 2014 Awad HA +4 more
europepmc +1 more source
Advanced Therapeutics, EarlyView.Emerging microphysiological systems reproduce the spatial, biochemical, and cellular complexity of the tumor microenvironment, surpassing 2D cultures and murine models. By integrating patient‐derived tumors, perfusable vasculature, and immune trafficking, these organ‐on‐chip platforms reveal mechanisms of immune evasion, predict therapeutic responses ...
Fabiana Moresi +5 more
wiley +1 more source
Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy
Advanced Therapeutics, EarlyView.This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar +7 more
wiley +1 more source
Evolution of Ocular Organ‐On‐Chip Systems for Disease Modelling and Drug Testing: Where are We Now?
Advanced Therapeutics, EarlyView.The rise in ophthalmic diseases due to aging, screen use, and environmental factors has driven demand for better ocular models. Traditional systems fall short, encouraging the development of organ‐on‐chip devices. These microfluidic platforms replicate eye tissue architecture, enable drug screening, and simulate ocular diseases.
Sara Trujillo
wiley +1 more source
Advanced Science, EarlyView.Midkine (MDK) is a mediator of the interaction between pancreatic cancer and beta cells. MDK, which originated from pancreatic ductal adenocarcinoma cells, exerted deleterious effects on paraneoplastic beta cells by binding to the SDC4 receptor on the beta cell surface and subsequently downregulating the Ras signaling pathway, thereby impairing insulin
Zengyu Feng +7 more
wiley +1 more source
Modelling suggests blood group incompatibility may substantially reduce SARS-CoV-2 transmission
, 2020 Ellis PJI.
europepmc +1 more source